Abstract
n-3 polyunsaturated fatty acids (PUFA) have been proposed as potential treatments for human heart failure. The cardioprotective effects of n-3 PUFA are supported by extensive cell culture, animal and human studies. Animal studies with n-3 PUFA have shown marked improvements in many independent risk factors for heart failure, including obesity, type II diabetes, insulin resistance, hypertension and inflammation. However, the evidence from observational studies, randomised controlled trials and meta-analyses that these benefits on risk factors lead to improvements in the symptoms of heart failure in patients is much less convincing. Further, most studies have used marine n-3 PUFA; the role of the plant-derived PUFA, α-linolenic acid (ALA), is even less clear. This discontinuity of scientific evidence from animal to human studies suggests that future studies should focus on defining the optimal dosage range and the efficacy of n-3 PUFA compared to standard treatments using standardised study designs. Further studies on ALA would seem justified.
Keywords: Alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, heart failure, omega-3 fatty acids.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure
Volume: 13 Issue: 1
Author(s): Hemant Poudyal and Lindsay Brown
Affiliation:
Keywords: Alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, heart failure, omega-3 fatty acids.
Abstract: n-3 polyunsaturated fatty acids (PUFA) have been proposed as potential treatments for human heart failure. The cardioprotective effects of n-3 PUFA are supported by extensive cell culture, animal and human studies. Animal studies with n-3 PUFA have shown marked improvements in many independent risk factors for heart failure, including obesity, type II diabetes, insulin resistance, hypertension and inflammation. However, the evidence from observational studies, randomised controlled trials and meta-analyses that these benefits on risk factors lead to improvements in the symptoms of heart failure in patients is much less convincing. Further, most studies have used marine n-3 PUFA; the role of the plant-derived PUFA, α-linolenic acid (ALA), is even less clear. This discontinuity of scientific evidence from animal to human studies suggests that future studies should focus on defining the optimal dosage range and the efficacy of n-3 PUFA compared to standard treatments using standardised study designs. Further studies on ALA would seem justified.
Export Options
About this article
Cite this article as:
Poudyal Hemant and Brown Lindsay, The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010013
DOI https://dx.doi.org/10.2174/1871530311313010013 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews The Neuropeptide Galanin Benefits Insulin Sensitivity in Subjects with Type 2 Diabetes
Current Protein & Peptide Science Cyclopentenone Prostaglandins as Anti-Inflammatory Agents: A Novel Therapeutic Strategy?
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Preterm Birth: Long Term Cardiovascular and Renal Consequences
Current Pediatric Reviews Maintenance of Gastrointestinal Glucose Homeostasis by the Gut-Brain Axis
Current Protein & Peptide Science Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters Hypercholesterolemia and Endothelium Dysfunction: Role of Dietary Supplementation as Vascular Protective Agents
Current Vascular Pharmacology Vascularization of Biomaterials for Bone Tissue Engineering: Current Approaches and Major Challenges
Current Angiogenesis (Discontinued) Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Cardiovascular Implantable Electronic Device Infections: Risk Scoring and Role of Antibiotic Envelope in Prevention
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Cardiac Adrenomedullin: Its Role in Cardiac Hypertrophy and Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Adrenomedullin and Oxidative Stress in Vascular Damage and Metabolic Disease
Current Hypertension Reviews Pharmacogenetic Study of CYP2C19 Variation and Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Atherothromboticrisk Patients in Thailand
Current Pharmacogenomics and Personalized Medicine Erratum
Inflammation & Allergy - Drug Targets (Discontinued) Structure and Inhibitor Binding Mechanisms of 11β -Hydroxysteroid Dehydrogenase Type 1
Current Chemical Biology Erythropoietin in Cancer: An Update
Current Molecular Medicine